Receive our newsletter – data, insights and analysis delivered to you
June 21, 2009

US Court Rules in Favour of Hospira Eloxatin Generic

The US District Court for New Jersey has ruled that Hospira has not infringed any laws in its pursuit of US Food and Drug Administration (FDA) approval for its generic version of Sanofi Aventis' chemotherapy medication Eloxatin. The company has tentative approval from the FDA for its ge

By cms admin

The US District Court for New Jersey has ruled that Hospira has not infringed any laws in its pursuit of US Food and Drug Administration (FDA) approval for its generic version of Sanofi Aventis’ chemotherapy medication Eloxatin.

The company has tentative approval from the FDA for its generic version of the product and expects full approval shortly based on the ruling.

Hospira vice-president of speciality pharmaceuticals Joshua Gordon said that the company was very pleased with the ruling.

“The launch of Hospira’s oxaliplatin injection will provide a high-quality, lower-cost alternative to patients,” Gordon said.

The Hospira version of Eloxatin will be one of the first generic versions available in the US to come in “solution” form.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU